false
0001701478
0001701478
2024-08-12
2024-08-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 12, 2024
AZITRA,
INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41705 |
|
46-4478536 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
|
|
|
|
|
21
Business Park Drive
Branford,
CT 06405 |
(Address
of principal executive offices)(Zip Code) |
(203)
646-6446 |
(Registrant’s
telephone number, including area code) |
(Former
name or former address, if changed since last report.) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock: Par value $0.0001 |
|
AZTR |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 Results of Operations and Financial Condition.
On
August 12, 2024, Azitra, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended
June 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
The
information in this Item 2.02, including the press release attached as Exhibit 99.1 hereto, is furnished pursuant to Item 2.02 but shall
not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date
hereof, regardless of any general incorporation language in such filing.
Item
9.01 Financial Statements and Exhibits
(d) |
Exhibits |
Method
Filing |
The
following exhibit is furnished with this report:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
AZITRA,
INC. |
|
|
Dated:
August 12, 2024 |
/s/
Francisco D. Salva |
|
Francisco
D. Salva |
|
Chief
Executive Officer |
Exhibit
99.1
Azitra,
Inc. Announces Q2 2024 Financial Results and Provides Business Updates
BRANFORD, Conn. — Azitra, Inc. (NYSE American: AZTR),
a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial
results for the three months ended June 30, 2024, and provided a business update.
Q2 2024 and Recent Business Highlights
|
● |
Completed
a follow-on offering of $10 million in gross proceeds expected to provide cash runway into
2025. With the recent financing, the company anticipates announcing multiple
clinical milestones |
|
|
|
|
● |
Strengthened
global intellectual property portfolio with newly granted and allowed patents |
|
|
|
|
● |
Exhibited
positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting |
|
|
|
|
● |
Presented
positive preclinical data of ATR-12 and clinical design in Netherton Syndrome at the ASGCT Annual Meeting |
|
|
|
|
● |
Opened
a Phase 1b clinical trial for ATR-12 for recruitment |
Francisco
Salva, CEO of Azitra commented:
“Azitra
is poised to achieve significant milestones in the second half of 2024 and beyond, propelling our pipeline forward. In Q3 2024, we expect
to dose the first Netherton syndrome patient with ATR-12. Additionally, we anticipate filing and clearing an Investigational New Drug
(IND) application for ATR-04, targeting epidermal growth factor receptor inhibitor (EGFRi) rash, a condition with high unmet need. This
milestone will expand our clinical pipeline to two clinical-stage programs.
Approximately
year-end 2024, we anticipate reporting initial safety
data from the ATR-12 Phase 1b trial in Netherton syndrome patients and providing an update on our Bayer license agreement. We expect
to initiate a first-in-human clinical trial with ATR-04 for EGFRi rash this fall.
Looking
ahead to mid-2025, we eagerly anticipate reporting topline data from the ATR-12 Phase 1b trial, a defining moment as we aim to demonstrate
biological proof of concept of our innovative approach in addressing this severe, rare skin disorder.
With
a clear roadmap, strong financial position, and dedicated team, Azitra is well-positioned to execute these milestones, deliver transformative
therapies to patients in need, and ultimately maximize shareholder value.”
Pipeline
and Upcoming Milestones
|
○ |
Q3
2024: First Netherton syndrome patient dosed with ATR-12 |
|
|
|
|
○ |
Q3
2024: New investigational new drug (IND) application filed and cleared with the FDA for a Phase 1/2 clinical study of ATR-04
in patients with dermal toxicity undergoing treatment with EGFR inhibitors (“EGFRi rash”) |
|
|
|
|
○ |
YE
2024: Initial safety data from first set of Netherton syndrome patients in the Phase 1b trial |
|
|
|
|
○ |
YE
2024: First patient dosed with ATR-04 for EGFRi rash by year end 2024 |
|
|
|
|
○ |
YE
2024: Bayer collaboration continues with update on license agreement expected by year end |
|
|
|
|
○ |
Mid
2025: Topline data of the Phase 1b trial with ATR-12 in Netherton syndrome patients expected |
Financial
Results for the Three Months Ended June 30, 2024
|
● |
Service
Revenue – Related Party: The Company generated $7,500 service revenue during the quarter ended June 30, 2024, compared
to $172,000 for the comparable period in 2023. |
|
|
|
|
● |
Research
and Development (R&D) expenses: R&D expenses for the quarter ended June 30, 2024, were $1.1 million compared to $0.8
million for the comparable period in 2023. |
|
|
|
|
● |
General
and Administrative (G&A) expenses: G&A expenses for the quarter ended June 30, 2024, were $1.5 million compared to $0.8
million for the comparable period in 2023. |
|
|
|
|
● |
Net
Loss was $2.6 million for the quarter ended June 30, 2024, compared to $5.1 million for the comparable period in 2023. |
|
|
|
|
● |
Cash
and cash equivalents: As of June 30, 2024, the Company had cash and cash equivalents of $0.8 million. |
About
ATR-12
ATR-12
(also known as ATR12-351) is an engineered strain of S. epidermidis that expresses a fragment of human lympho-epithelial
Kazal-type-related inhibitor (LEKTI) protein, which is missing in patients with Netherton syndrome, a chronic and sometimes fatal
disease of the skin estimated to affect approximately 20,000 patients globally. ATR-12 has been engineered to deliver missing LEKTI protein
when applied topically to Netherton syndrome patients. Azitra has an open IND for a Phase 1b clinical trial that is actively recruiting
adult Netherton syndrome patients (NCT06137157). Azitra has identified Netherton syndrome patients for enrollment in its 12-patient,
Phase 1b clinical trial, which will assess safety, tolerability, and efficacy endpoints.
About
ATR-04
ATR-04
is a live biotherapeutic product candidate including an isolated, naturally derived S. epidermidis strain that was
engineered to be safer by deleting an antibiotic resistance gene and engineering auxotrophy to control the growth of ATR-04. ATR-04 is
in development for EGFR inhibitor (“EGFRi”) associated rash, which is caused by the suppression of skin immunity by
EGFRis and subsequent inflammation and often elevated levels of IL-36γ and S. aureus. There are approximately 150,000 patients
suffering from EGFRi rash in the United States. Azitra plans to initiate a Phase 1/2 clinical study in patients undergoing EGFRi rash
by year end 2024.
About
Azitra, Inc.
Azitra,
Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using
engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial
library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform
is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company’s
library of strains for drug like molecules. The Company’s initial focus is on the development of genetically engineered strains
of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for
engineering of dermatologic therapies. For more information, please visit https://azitrainc.com/.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,”
“estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,”
“plans,” “possible,” “potential,” “seeks,” “will,” and variations of these
words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that
are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without
limitation, statements regarding the expected timing of the presentation of data from the Phase 1b study of ATR-12, the filing of an
IND application, and the presentation of data from our Phase 1b for ATR-04, the IND filing for ATR-01, the timing of having a signed
license agreement with Bayer, and statements about our clinical and pre-clinical programs, and corporate and clinical/pre-clinical strategies.
Any
forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of
this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely
from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to
that we may fail to successfully complete our Phase 1b trial for ATR-12 and pre-clinical studies of other product candidates and obtain
required approval before commercialization; our product candidates may not be effective; there may be delays in regulatory approval or
changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate;
we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge;
we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract
and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are
dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional
risks concerning Azitra’s programs and operations are described in its registration statement on Form S-1, which is on file with
the SEC, and in its most recent quarterly report on Form 10-Q to be filed with the SEC. Azitra explicitly disclaims any obligation to
update any forward-looking statements except to the extent required by law.
Contact
Norman
Staskey
Chief
Financial Officer
staskey@azitrainc.com
Hayden
IR
James
Carbonara
(646)
755-7412
james@haydenir.com
Condensed
Statement of Operations
(Unaudited)
| |
Three months Ended June 30, | |
| |
2024 | | |
2023 | |
Service revenue – related party | |
$ | 7,500 | | |
$ | 172,000 | |
Total revenue | |
| 7,500 | | |
| 172,000 | |
| |
| | | |
| | |
Operating expenses: | |
| | | |
| | |
General and administrative | |
| 1,549,228 | | |
| 844,639 | |
Research and development | |
| 1,118,552 | | |
| 754,951 | |
Total operating expenses | |
| 2,667,780 | | |
| 1,599,590 | |
| |
| | | |
| | |
Loss from operations | |
| (2,660,280 | ) | |
| (1,427,590 | ) |
| |
| | | |
| | |
Other income (expense): | |
| | | |
| | |
Interest income | |
| 16,268 | | |
| 264 | |
Interest expense | |
| (1,782 | ) | |
| (76,187 | ) |
Change in fair value of convertible note | |
| - | | |
| (2,830,100 | ) |
Change in fair value of warrants | |
| 4,272 | | |
| (94,232 | ) |
Other income (expense) | |
| 9,529 | | |
| (1,683 | ) |
Total other income (expense) | |
| 28,287 | | |
| (3,001,938 | ) |
| |
| | | |
| | |
Net loss before income taxes | |
| (2,631,993 | ) | |
| (4,429,528 | ) |
| |
| | | |
| | |
Income tax expense | |
| - | | |
| - | |
| |
| | | |
| | |
Net loss | |
$ | (2,631,993 | ) | |
| (4,429,528 | ) |
Dividends on preferred stock | |
| - | | |
| (643,267 | ) |
Net loss attributable to common shareholders | |
$ | (2,631,993 | ) | |
| (5,072,795 | ) |
Net loss per Share, basic and diluted | |
$ | (2.74 | ) | |
$ | (70.83 | ) |
Weighted average common stock outstanding, basic and diluted | |
| 960,146 | | |
| 71,622 | |
Condensed
Balance Sheets
(Unaudited)
| |
June 30, | | |
December 31, | |
| |
2024 | | |
2023 | |
Assets | |
| | |
| |
Current Assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 803,082 | | |
$ | 1,795,989 | |
Other receivables | |
| 111,895 | | |
| 223,474 | |
Prepaid expenses and other current assets | |
| 420,828 | | |
| 516,116 | |
Total current assets | |
$ | 1,335,805 | | |
$ | 2,535,579 | |
Property and equipment, net | |
| 658,731 | | |
| 710,075 | |
Other assets | |
| 1,888,018 | | |
| 1,869,832 | |
Total assets | |
$ | 3,882,554 | | |
$ | 5,115,486 | |
Liabilities, and stockholders’ equity | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 996,700 | | |
$ | 897,272 | |
Current financing lease liability | |
| 15,317 | | |
| 14,600 | |
Current operating lease liability | |
| 293,026 | | |
| 307,655 | |
Accrued expenses | |
| 434,103 | | |
| 383,668 | |
Total current liabilities | |
| 1,739,146 | | |
| 1,603,195 | |
Long-term financing lease liability | |
| 18,329 | | |
| 26,169 | |
Long-term operating lease liability | |
| 395,987 | | |
| 537,523 | |
Warrant liability | |
| 2,926 | | |
| 35,453 | |
Total liabilities | |
| 2,156,388 | | |
| 2,202,340 | |
Stockholders’ equity | |
| | | |
| | |
Common stock | |
| 96 | | |
| 40 | |
Additional paid-in capital | |
| 55,889,271 | | |
| 51,510,269 | |
Accumulated deficit | |
| (54,163,201 | ) | |
| (48,597,163 | ) |
Total stockholders’ equity | |
| 1,726,166 | | |
| 2,913,146 | |
Total liabilities and stockholders’ equity | |
$ | 3,882,554 | | |
$ | 5,115,486 | |
v3.24.2.u1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Azitra (AMEX:AZTR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Azitra (AMEX:AZTR)
Historical Stock Chart
From Oct 2023 to Oct 2024